QDEL QuidelOrtho Corp
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1906324 · Fiscal year ends 01/01
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.5%
TTM net income YoY68.7%
TTM EPS YoY69.0%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—
Margins
Gross margin44.2%
Operating margin-4.9%
Net margin-14.2%
FCF margin-4.5%
EBITDA margin12.9%
Returns
ROE-19.3%
ROA-6.4%
ROIC (approx.)-2.2%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets69.0%
Debt / equity1.64x
Current ratio1.36x
Interest coverage-0.60x
Cash quality & payout
Operating cash flow / net income-0.02x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 |
|---|---|---|
| Income statement | ||
| Revenue | $2.73B | $2.78B |
| Cost of revenue | $1.46B | $1.50B |
| Gross profit | $1.27B | $1.29B |
| R&D expense | $186.20M | $218.70M |
| SG&A expense | $746.30M | $766.80M |
| Operating income | -$919.20M | -$1.96B |
| Interest expense | $177.60M | $163.50M |
| Pretax income | -$1.11B | -$2.13B |
| Income tax | $24.10M | -$79.50M |
| Net income | -$1.13B | -$2.05B |
| EBITDA | -$477.20M | -$1.51B |
| EPS (basic) | -16.69 | -30.54 |
| EPS (diluted) | -16.69 | -30.54 |
| Weighted avg. shares (diluted) | 67.80M | 67.20M |
| Banking | ||
| Net interest income | — | -$163.50M |
| Balance sheet | ||
| Cash & equivalents | $169.80M | $98.50M |
| Short-term investments | — | $0 |
| Receivables | $417.00M | $282.40M |
| Inventory | $577.60M | $533.70M |
| Current assets | $1.45B | $1.22B |
| PP&E, net | $1.36B | $1.38B |
| Goodwill | $0 | $649.50M |
| Intangibles | $2.56B | $2.74B |
| Total assets | $5.77B | $6.42B |
| Current liabilities | $966.10M | $998.80M |
| Short-term debt | $178.30M | $341.80M |
| Long-term debt | $2.47B | $2.14B |
| Total debt | $2.65B | $2.48B |
| Total liabilities | $3.85B | $3.44B |
| Shareholders' equity | $1.92B | $2.98B |
| Net debt | $2.48B | $2.38B |
| Shares outstanding | 67.90M | 67.30M |
| Cash flow statement | ||
| Operating cash flow | $105.20M | $83.00M |
| Capital expenditure | $188.20M | $195.10M |
| Free cash flow | -$83.00M | -$112.10M |
| Investing cash flow | -$192.70M | -$149.90M |
| Financing cash flow | $155.80M | $48.80M |
| Depreciation & amortization | $442.00M | $453.40M |
| Stock-based compensation | $45.90M | $42.10M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.